Newsroom

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Charles Schwab Investment Management, Inc. (CSIM) in its capacity as investment advisor to clients. CSIM expressly disclaims beneficial ownership of the shares described in this form 8.3. (b) Owner or controller of interests and short positions...

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Ratings of “a+” (Excellent) of Zenith Insurance Company and ZNAT Insurance Company. The outlook of these Credit Ratings (ratings) is stable. These companies comprise Zenith National Insurance Group (Zenith) and are domiciled in Woodland Hills, CA.The ratings reflect Zenith’s balance sheet strength, which AM Best assesses as very strong, as well as its adequate opera...

SAN FRANCISCO--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Farallon Capital Management, L.L.C. (on behalf of funds managed jointly with Farallon Capital Europe LLP and Farallon Partners, L.L.C.) (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming...

NEW YORK--(BUSINESS WIRE)--Susan Estrich of Estrich Goldin, attorney for Leon Black, offered the following comment on the federal district court’s order dismissing with prejudice Jane Doe’s lawsuit against Leon Black: “We are pleased that Judge Clarke dismissed with prejudice Jane Doe’s lawsuit against Leon Black. “This lawsuit never should have been filed in the first place. Jane Doe’s complaint was a work of fiction, authored by the Wigdor firm, filled with ugly lies and vicious fabrications....

SHENZHEN, China--(BUSINESS WIRE)--The Phase 1 trial will assess the safety, tolerability, pharmacokinetics and preliminary antitumor activity of NW001 in patients with advanced tumors....

中国深圳--(BUSINESS WIRE)--(美国商业资讯)-- 深圳微芯生物科技股份有限公司（简称“微芯生物”，688321.SH）宣布，其与成都微芯新域生物技术有限公司合作开发的全球首创表观免疫偶联药物（EIMAC）NW001的首次人体临床试验申请已获中国国家药监局批准。该I期临床将评估NW001在晚期恶性肿瘤人群中的安全性、耐受性、药代动力学以及初步抗肿瘤活性。 尽管免疫检查点抑制剂已改变多种晚期肿瘤的治疗格局，但免疫“冷”肿瘤、原发或获得性耐药仍是当前临床面临的突出难题。提升免疫治疗疗效、克服耐药瓶颈，成为下一代肿瘤免疫药物开发的关键方向。 NW001是一款表观免疫偶联药物（EIMAC，Epigenetic Immune-Modulating Antibody Conjugate）。其抗体部分为人源化PD-L1单抗，并通过独特设计偶联全新改进的组蛋白去乙酰化酶抑制剂（HDACi）荷载。NW001与细胞表面的PD-L1结合后发生内吞，在细胞内裂解并释放高活性的小分子HDACi，发挥表观免疫的综合抗肿瘤活性。该设计有望在肿瘤细胞内精准释放表观调控荷载，降低全身载荷，突破现有免疫治...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 15.10.2026 FTFX IE00BD5HBQ97   58,116.00 USD   1,672,452.94   28.778  ...

DALLAS--(BUSINESS WIRE)--Copart, Inc. (NASDAQ: CPRT) (“Copart”), a global leader in online vehicle auctions, today announced the successful completion of its acquisition of ACV Auctions Inc. (NYSE: ACVA) (“ACV”). “We are pleased to complete the acquisition of ACV, which is an important milestone for Copart as we continue to deliver on our growth strategy,” said Jay Adair, Chief Executive Officer of Copart. “With ACV now part of the Copart family, we have established an industry-leading, fully c...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 15.10.2026 FXGB LN IE00BD5HBR05   69,032.00 GBP   1,500,528.98   28.804  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest US Equity Max Buffer UCITS ETF - March 15.10.2026 MMAR.LN IE0002PPCMH6   50,002.00 USD   1,352,265.31   27.044  ...